Antibodies

18 Oct 2019 Nplate® (romiplostim) Now Approved For Earlier Use In Adults With Immune Thrombocytopenia
18 Oct 2019 Merck Receives Positive EU CHMP Opinion for Two New Regimens of KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma
18 Oct 2019 CHMP Grants Positive Opinion for Expanded Use of Janssen’s Darzalex (daratumumab) for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible
18 Oct 2019 ADC Therapeutics Doses First Patients in Pivotal Phase 2 Clinical Trial of ADCT-301 in Patients with Relapsed or Refractory Hodgkin Lymphoma
18 Oct 2019 EVENITY® (romosozumab) Receives Positive CHMP Opinion for the Treatment of Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture
17 Oct 2019 Bird Rock Bio Announces Successful Completion of Phase 1B Safety Study and Readiness for Phase 2B Study of Nimacimab in Patients with Diabetic Kidney Disease
17 Oct 2019 [Fam-] Trastuzumab Deruxtecan Granted FDA Priority Review for Treatment of Patients With HER2-positive Metastatic Breast Cancer
17 Oct 2019 NeuClone Announces First Human Dose of Stelara® (Ustekinumab) Biosimilar Candidate in Phase I Clinical Trial
17 Oct 2019 Bimekizumab Phase 3 Psoriasis Study Meets All Endpoints, Achieving Significantly Greater Efficacy Versus Placebo and Ustekinumab
17 Oct 2019 Ichnos Sciences Launches as New, Independent, Leading-Edge Biotech Dedicated to Outpacing Disease
16 Oct 2019 Neurimmune and TVM Capital Life Science Announce the Initiation of AL-S Pharma's Phase 1 Study of AP-101 for the Treatment of ALS
16 Oct 2019 Amphivena Initiates Solid Tumor Clinical Trial
16 Oct 2019 Adaptate Biotherapeutics formed to develop antibody-based therapies that modulate gamma delta T-cells
15 Oct 2019 PhaseBio Announces First Patient Dosed in Phase 2b Clinical Trial of PB2452 for Reversal of the Antiplatelet Activity of Ticagrelor
15 Oct 2019 Affimed Reports Progress on Key Clinical Development Programs
15 Oct 2019 Immutep reports positive final efficacy data from TACTI-mel trial in melanoma
14 Oct 2019 I-Mab Biopharma and MorphoSys Announce IND Clearance to Initiate Clinical Trials of TJ202/MOR202 for the Treatment of Multiple Myeloma in Mainland China
14 Oct 2019 Femtogenix Presents Efficacy and Toxicity Data on Antibody Drug Conjugates Containing New Generation of DNA-binding Therapeutic Payloads
14 Oct 2019 Phase III PEMPHIX Study Shows Genentech’s Rituxan (Rituximab) Superior to Mycophenolate Mofetil in Patients With Pemphigus Vulgaris
11 Oct 2019 Kodiak Sciences Treats First Patients in DAZZLE Pivotal Study of KSI-301 in Wet Age-Related Macular Degeneration
10 Oct 2019 Alder BioPharmaceuticals® Announces First-in-Human Dosing in Phase 1 ALD1910 Study for Preventive Treatment of Migraine
10 Oct 2019 Oncologie Announces First Patient Enrolled in Global Phase 2 Study of Bavituximab Plus KEYTRUDA® (Pembrolizumab) for Advanced Gastric or Gastroesophageal Cancer
10 Oct 2019 Galderma Advances Phase 3 Clinical Study with Nemolizumab in Moderate-to-Severe Atopic Dermatitis
09 Oct 2019 Dermira Announces Initiation of Phase 3 Program Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
09 Oct 2019 Annexon Biosciences Reports Top-line Phase 1b Results for Novel C1q Inhibitor ANX007 in Glaucoma

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top